Biotech Values

[DewDiligence]

HGSI – Major misstatement in the Wash Post:

http://www.washingtonpost.com/wp-dyn/content/article/2008/01/23/AR2008012303420.html

>>
The analyst, William Sargent of Banc of America, said Human Genome Sciences said the efficacy of its lower-dose treatments has been above 90 percent, which should be enough to file for regulatory approval.
<<

Either Sargent or the Wash Post botched the story (probably the latter).

What HGS actually said on the CC is that the statistical power for hitting the primary non-inferiority endpoint on the lower dose is 90%. This has nothing to do with “90% efficacy,” the phrase used in the article.